NCT05111067View on ClinicalTrials.gov

Molecular Subtyping of Triple-negative Breast Cancer and African Ancestry-related Immunogenicity

CompletedOBSERVATIONAL

Enrollment

120

Participants

Timeline

Start Date

December 1, 2021

Primary Completion Date

December 1, 2023

Study Completion Date

December 1, 2023

Conditions

Triple Negative Breast Cancer

Interventions

GENETIC

DNA and whole transcriptome mRNA sequencing

DNA and whole transcriptome mRNA sequencing, including total mutational burden and microsatellite instability, will be performed using the TruSight Oncology 500 (TSO500) platform (Illumina Canada, Ulc).

Trial Locations (1)

B2Y 1A7

Nova Scotia Health, Halifax

All Listed Sponsors

collaborator

Obafemi Awolowo University

OTHER

lead

Nova Scotia Health Authority

OTHER

NCT05111067 - Molecular Subtyping of Triple-negative Breast Cancer and African Ancestry-related Immunogenicity | Biotech Hunter | Biotech Hunter